Commentary: Response to "Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study"

J Am Acad Dermatol. 2024 Sep 30:S0190-9622(24)02901-3. doi: 10.1016/j.jaad.2024.08.082. Online ahead of print.

Authors

Affiliations

¹ Regeneron Pharmaceuticals Inc., Tarrytown, New York. Electronic address: tien.nguyen2@regeneron.com.
² Regeneron Pharmaceuticals Inc., Tarrytown, New York.
³ Sanofi, Cambridge, Massachusetts.
⁴ Regeneron Pharmaceuticals Inc., Dublin, Ireland.
⁵ Sanofi, Amsterdam, Netherlands.
⁶ Sanofi, Mumbai, India.

PMID: 39357651
DOI: 10.1016/j.jaad.2024.08.082

No abstract available

Keywords: analyses; atopic dermatitis; cutaneous T-cell lymphoma; dupilumab; safety; severity.

Publication types

Letter